By Chris Wack Biopharmaceutical companies BioNTech SE and Duality Biologics Co. Ltd. have entered into exclusive license and collaboration agreements to develop, manufacture and commercialize... | April 3, 2023
Germany's BioNTech said
on Monday that it signed a deal with Chinese biotech company
DualityBio to co-develop and commercialize two cancer antibody
drug candidates. DualityBio will... | April 3, 2023
BioNTech and Duality Biologics have entered into exclusive license and collaboration agreements for two ADC assets: thus adding ADCs as an additional drug class in BioNTech’s oncology portfolio.
BioNTech’s alliance with DualityBio gives it two antibody drug conjugate (ADC) candidates, the most advanced of which is in mid-stage clinical development for solid tumors. It addresses the same target as a potential blockbuster AstraZeneca drug.
Consolidated Financial Statements BioNTech SE, Mainz as of December 31, 2022 Consolidated Statements of Profit or Loss Years ended ... | March 29, 2023
MAINZ, Germany, March 28, 2023 -- BioNTech SE today announced that it has entered into a new share repurchase program , pursuant to which the Company may purchase American Depositary Shares,... | March 28, 2023
By Cecilia Butini BioNTech SE on Monday posted lower revenue and profit for the fourth quarter of 2022, and said it expects a fall in revenue from its Covid-19 vaccines in the current year.
... | March 27, 2023